浅层X线治疗12例难治性掌跖疣疗效分析

目的:评价2021年9月至2022年6月于我院门诊诊治的12例掌跖疣患者使用浅层X线治疗的效果。方法:12例患者均进行过多次冷冻治疗且效果不佳,判定为难治性掌跖疣,其疣体厚度均在3～5 mm。对这12例患者均给予浅层X线放射治疗,每次剂量为5 Gy,管电压70 kV,每周1次,治疗3次,治疗结束后随访1个月。结果:12例患者已经结束治疗。10例患者最终皮损消退,治疗结束后1个月随访未复发,其中1例患者治疗结束后出现皮损周围感染,4周后治愈,未遗留瘢痕及色素沉着。1例多发跖疣的男性患者皮损未完全消退,结束治疗后有新发皮损判定为复发。1例多发跖疣的男性患者皮损消退不明显,失访。结论:本研究中浅层X线对难治性掌跖疣显示出了较好疗效,不良反应相对较少,复发率较低,疗程短。     

浅层X线放射治疗家族性良性慢性天疱疮

目的： 评价浅层X线治疗5例家族性良性慢性天疱疮(HHD)患者的疗效。 方法： 对5例HHD患者的腋窝或腹股沟等部位行浅层X线治疗,每周1次,共3-4次,累积放射量9-12Gy。 结果： 5例患者随访4～35个月后,3例皮疹完全消退,2例部分改善,不良反应主要为色素沉着。结论： 浅层X线放射疗法治疗家族性良性慢性天疱疮安全有效。     

联合使用浅层X线照射治疗60例跖疣的临床疗效观察

目的观察使用联合浅层X线照射治疗跖疣的临床疗效观察。方法选择门诊跖疣患者60例,随机分为对照组与治疗组各30例。基础治疗采用重组人干扰素(IFN)α-2b软膏,在疣体部位适量外涂,4次/d,涂药后按摩患处2～3 min以助药物吸收。对照组采用液氮冷冻治疗,2周1次,12周为1个疗程。治疗组在采用浅层X线照射跖疣部位,1次/周,6次为1个疗程,治疗2个疗程(12周)。治疗结束后观察临床疗效、复发情况及不良反应。结果第1个疗程治疗结束时对照组总有效率60.0%,治疗组总有效率70.0%。第2个疗程治疗结束时对照组总有效率73.3%,治疗组总有效率83.3%。2个疗程后3个月随访复发率对照组33.3%,治疗组16.7%。治疗过程中不良反应治疗组少于对照组。结论联合使用浅层X线照射治疗跖疣,临床治疗效果满意,临床上值得推广。     

CO_2激光联合浅层X线照射治疗肛周尖锐湿疣的临床疗效观察

目的:观察应用CO_2激光联合浅层X线照射治疗肛周尖锐湿疣的疗效及复发率。方法:肛周尖锐湿疣患者132例,随机分为治疗组和对照组两组。对照组用CO_2激光治疗,常规皮肤消毒,局麻后每个皮损连续点灼,范围超过疣体基底部,术毕可外涂抗炎药膏,保护创面。治疗组用CO_2激光联合SRT-100浅层X线照射治疗,CO_2激光清除疣体后即刻照射1次,3d,7d,15d各照射1次,4次为1疗程,结束后随访3个月。结果:对照组治愈率52.24%,复发率为47.76%;治疗组治愈率86.16%,复发率为13.84%。治疗组与对照组的治愈率及3个月后的复发率比较,差异均有统计学意义(P0.05)。结论:CO_2激光联合SRT-100浅层X线照射治疗能有效治疗肛周尖锐湿疣,具有安全,治愈率高,复发率低,患者依从性好。     

低剂量浅层X线治疗婴幼儿皮肤黏膜血管瘤

目的 探讨低剂量浅层X线治疗婴幼儿皮肤黏膜血管瘤的治疗条件、剂量及预后。方法 采用西门子公司DermopanⅡ型浅层X线治疗机，根据患儿血管瘤的深度、部位分别选用管电压29、43和50kV进行照射，每周1-2次，每次剂量1-2Gy，照射总量一般5-10Gy，最多为20Gy。结果 267例中痊愈230例，显效24例，有效10例，无效3例。治愈率为86．14％，有效率95．13％。结论 本方法操作简便，安全，无痛苦，费用低，治愈率较高，易为患儿及家长接受。     

重组人干扰素α-2b皮损内注射治疗寻常疣疗效观察

目的 观察干扰素皮损局部注射治疗寻常疣疗效。方法 采用重组人干扰素α-2b注射液100万u加2％利多卡因1ml混合进行寻常疣皮损局部注射。结果 经过1～4次注射后，76例207枚疣体消退178枚，痊愈率为86．0％，有效率为93．2％。结论 干扰素皮损内注射治疗寻常疣，操作较简便，损伤亦较小，患者痛苦小，疗效满意。     

X线联合卡替洛尔治疗婴幼儿血管瘤疗效观察

目的:评价低剂量浅层X线联合卡替洛尔滴眼液治疗婴幼儿血管瘤的疗效及安全性。方法:对我科门诊2017年6月至2018年6月确诊的婴幼儿血管瘤患者予SRT-100 TM放射治疗系统低剂量浅层X线照射,管电压50 KV,剂量150 cGy,1次/周,共3次,结束后外涂卡替洛尔滴眼液,随访1年。结果:完成治疗和随访的患者72例,其中显效56例,好转12例,进步3例,无效1例,有效率为94.4%;不良反应仅两例患儿局部皮肤出现暂时性色素沉着,未见其他不良反应。结论:低剂量浅层X线照射联合卡替洛尔滴眼液外涂治疗婴幼儿血管瘤安全有效。     

5-氨基酮戊酸光动力疗法治疗寻常疣8例及跖疣12例临床观察

目的探讨5-氨基酮戊酸光动力(ALA-PDT)疗法治疗寻常疣及跖疣的疗效及安全性。方法对入选的8例寻常疣及12例跖疣患者予5-氨基酮戊酸光动力疗法治疗,随访3个月后评价疗效。结果 20例患者经3～7次治疗后均痊愈,且无明显不良反应,平均治疗2.8次,有9例治疗3次,8例治疗4次,2例治疗5次,1例治疗7次,均未见复发和不良反应。结论 5-氨基酮戊酸光动力疗法治疗寻常疣及跖疣疗效好,安全可靠。     

人成纤维细胞干扰素在寻常疣治疗中的应用

本文报道利用双盲试验方法,在80例双侧肢体患有寻常疣的病人一侧肢体的疣内注射人成纤维细胞干扰素(HuIFN～β)0.1×10~6国际单位,每周注射1次,在另侧肢体的相应部位的疣内注入安慰剂.每周观察1次.疗程以一侧肢体寻常疣消退或满10次注射为止.仅64例完成疗程,其中用干扰素治疗的疣有42例痊愈,10例显效,显效率共占81%以     

浅层X线照射治疗掌跖疣疗效观察

1临床资料选择2002年12月~2006年6月本科门诊掌跖疣患者125例,均符合相关诊断标准[1]。男87例,女38例;年龄13~60岁(平均28.2岁);病程3~18个月(平均4.3个月);患者疣体数1~10余个,呈散在或集簇性分布,患者共分成384个照射野,单个疣体面积为0.3 cm×0.2 cm~3.0 cm×4.0 cm。其中58例曾接受过激光、冷冻或外用药物治疗。2治疗方法采用STX50-3A浅层X线治疗机(日本)照射,照射前温水浸泡掌跖部30 min,剪去表面的角质层,以无痛不出血为宜,用铅橡皮垫保护周围正常皮肤,每照射野每次2~3Gy,2次/周,5次为1疗程。疣体消失不彻底者1个月后重复第2个疗程…     

132例皮肤疣组织人乳头瘤病毒分型检测

目的 探讨皮肤疣组织中人乳头瘤病毒（HPV）的感染率和病毒型别。方法 门诊皮肤疣患者132例中寻常疣46例,跖疣38例,扁平疣48例。以特异性DNA序列为模板设计引物,进行PCR扩增,电泳,对结果进行分析。 结果 132例皮肤疣中,HPV阳性128例,感染率为97.0%,其中HPV2型阳性111例,感染率为84.1%。寻常疣、跖疣感染主要为HPV2、HPV1型,扁平疣感染主要为HPV2、HPV10、HPV3、HPV1型。89例为多重感染,感染率为67.4%,其中二重感染率为41.7%（55例）,三重感染率为21.2%（28例）,四重感染率为4.6%（6例）;寻常疣多重感染率为50.0%（23/46）,跖疣为76.3%（29/38）,扁平疣77.1%（37/48）。多重感染中,以HPV1 + 2型最多,有35例（39.3%）,其次为HPV1 + 2 + 10型,有12例（13.5%）。 结论 遵义皮肤疣感染以HPV2型为主,其次为1型;2型与多种皮肤疣感染有关;皮肤疣中多重感染率较高,其中扁平疣多重感染率最高;新发现HPV3、10型感染寻常疣,HPV10型感染跖疣,HPV1、7型感染扁平疣。     

复方硝酸溶液治疗寻常疣多中心、随机开放、平行对照临床试验

目的 评价复方硝酸溶液(商品名思可得)治疗寻常疣的疗效和安全性,并与冷冻疗法进行比较。方法 采用多中心、随机开放、平行对照的临床试验。结果 主要疗效靶疣体清除率中思可得组为71.6%,冷冻组为77.5%(P=0.451)。次要疗效其他疣体清除率中思可得组为58.7%,冷冻组为75.3%(P=0.034)。思可得组不良反应发生率为4.1%,冷冻组为1.4%(P>0.05)。结论 思可得治疗寻常疣简便、安全、有效。     

Successful treatment of recalcitrant warts with topical squaric acid in immunosuppressed child

Abstract:  Although spontaneous resolution of verrucous vulgaris is the norm, many treatment modalities are available including local destruction, chemotherapy, immunotherapy, and sensitizing agents. The choice of treatment will vary with patient's age and desire for treatment, prior treatments, potential side effects, location of lesions, and patient's immune status. Treatment of verruca vulgaris in immunosuppressed patients presents therapeutic challenges as lesions in this population are often refractory to conventional modalities. Here we present a case of successful treatment of recalcitrant warts with topical squaric acid in an immunosuppressed child.     

Characterization and analysis of human papillomaviruses of skin warts

We analysed human papillomavirus (HPV) infections in 61 tissue specimens of skin warts of Taiwanese patients by DNA hybridization. The prevalence of HPV infection was 69% by Southern blot hybridization. The typing of HPVs was performed by dot blot hybridization under highly stringent conditions with each probe separately. The prevalence of HPV-1, 2/3, 4, 5, 8, 11, 16 and 18 in skin warts was 13, 7, 16, 2, 0, 5, 2 and 8%, respectively. Chi-squared analysis revealed that there was a correlation between HPV type and copy number. Most HPV-4-induced warts were verruca vulgaris. HPV-1 DNA was detected in verruca plantaris and verruca vulgaris. No specific histopathological features were found to be indicative of the presence or absence of HPV, or of the various types of HPV infection.     

Levamisole therapy for multiple warts

Levamisole, a wide-spectrum antiparasitic drug, increases cellular immunity in vivo and in vitro. Patients with verruca vulgaris may have defective cell mediated immune mechanisms. Levamisole was given to twenty-two patients with multiple warts, 5 mg/kg body weight on 3 consecutive days every fortnight. Patients' lymphocytes were studied for E-rosette formation before therapy. E-rosette counts were lower in patients compared with controls and a significant increase was obtained after in vitro incubation with levamisole. Seventeen patients were cured in 1-4 months, there were four failures and one patient showed marked improvement. It is concluded that patients with multiple warts have defective cell-mediated mechanisms as far as the E-rosette count is concerned and that levamisole increases in vitro E-rosette formation and is useful in the treatment of these patients.     

寻常疣脉冲染料激光治疗前后激光散斑成像观察

目的 采用激光散斑衬比分析（LSCA）技术无创性观察分析不同部位和大小的疣体激光治疗前后的血流变化,以探讨LSCA技术用于激光治疗寻常疣疗效量化评价的可能性。 方法 采用脉冲染料激光（PDL）治疗17例寻常疣患者30处病灶,使用LSCA观察和记录治疗前、治疗后10 min、治疗后3周疣体及其周围正常皮肤血流变化及散斑流速指数（SFI）值,以评估PDL治疗的效果。 结果 寻常疣患者治疗前疣体的血流SFI值（11.600 ± 1.190）高于周围正常皮肤（5.280 ± 0.481）,差异有统计学意义（t = 8.169,P < 0.01）。与治疗前疣体SFI值相比,治疗后10 min（3.112 ± 0.484）和治疗后3周时（7.315 ± 1.083）疣体血流SFI值均显著降低（t值分别为4.407、3.294,均P < 0.01）,治疗后3周高于治疗后10 min（t = 4.646,P < 0.01）。激光治疗后10 min疣体周围正常皮肤血流SFI值（20.260 ± 2.063）较治疗前显著升高（t = 6.770,P < 0.01）,但治疗后3周（4.941 ± 0.616）又较治疗后10 min显著降低（t = 6.964,P < 0.01）,治疗后3周与治疗前相比,差异无统计学意义（t = 0.378,P = 0.707）。激光治疗的效果与疣体大小和分布部位有关, < 0.5 cm2疣体激光治疗后血流改变较 ≥ 0.5 cm2疣体更大,差异有统计学意义（t = 2.287,P < 0.05）;不同分布部位的疣体激光治疗后血流改变不同（F = 15.71,P < 0.01）,不同部位疣体血流SFI值改变由大到小依次为手指、足背、足趾、掌跖、甲周。 结论 寻常疣疣体内血流较正常皮肤明显升高,PDL可以凝固气化疣体内血管达到治疗目的。利用LSCA血流监测技术,能定量观察到激光治疗寻常疣前后的血流变化。     

Salicylic acid in karaya gum patch as a treatment for verruca vulgaris

A clinical study was conducted to evaluate the efficacy of a new delivery system for administering salicylic acid for the treatment of verruca vulgaris. The study compared wart resolution among volunteers who used karaya gum patches. The cure rate was 69% for warts treated with patches containing salicylic acid, which was significantly higher (p less than 0.01) than for warts treated with control patches (35%).     

Bleomycin in the treatment of recalcitrant warts

Bleomycin is gaining increasing popularity in the treatment of warts, but its efficacy has not been examined in well-controlled studies. We evaluated bleomycin in a double-blind placebo-controlled crossover study in recalcitrant warts treated unsuccessfully by conventional methods. Patients were assigned alternately to placebo or bleomycin groups and treated by intralesional injections of bleomycin, 1 U/ml, or saline, at 2-week intervals. If warts persisted, patients were changed after two injections to the alternate group and retreated with up to two further injections. Forty patients entered the study. Of 151 warts treated with intralesional bleomycin, 123 were cured after one or two injections (81%). The cure rate for plantar warts (60%) was lower than that for periungual warts (94%) and warts elsewhere on the extremities (95%). Fifty-five warts were injected with normal saline; none was cured. Responding warts showed a hemorrhagic eschar and healed without scarring, atrophy, or pigmentary change. Pain was usually mild and patient acceptance superior to that with liquid nitrogen. There was no evidence of systemic toxicity. Bleomycin is highly efficacious in the treatment of recalcitrant warts, is convenient, and has high patient acceptance. Long-term safety requires further study.